Skip to content
Search

Latest Stories

NHS to offer new Produodopa drug for Parkinson's patients

Produodopa combines foslevodopa and foscarbidopa, which together increase the levels of dopamine in the brain, a crucial neurotransmitter for regulating movement

NHS to offer new Produodopa drug for Parkinson's patients

NHS England is set to introduce a groundbreaking treatment for individuals suffering from advanced Parkinson's disease, benefiting up to 1,000 patients. This innovative approach involves a wearable device that administers medication continuously throughout the day and night.

The treatment, known as Produodopa, leverages a pump system to deliver a constant flow of medication directly into the patient's bloodstream, offering a new level of symptom management, the BBC reported.


This method stands in stark contrast to the current regimen for many, which can involve ingesting over 20 pills daily, often resulting in fluctuating control over symptoms. For some, the alternative has been receiving medication through a permanent feeding tube.

Produodopa combines foslevodopa and foscarbidopa, which together increase the levels of dopamine in the brain, a crucial neurotransmitter for regulating movement.

The medication is administered via a cannula placed under the skin, controlled by a compact pump that ensures a consistent dosage 24 hours a day.

Patients also have the option to manually adjust the dosage for additional relief as needed.

James Palmer, NHS England's medical director for specialised services, expressed enthusiasm about the rollout, highlighting its significance for patients who are ineligible for other treatments like deep brain stimulation.

He anticipates that this therapy will significantly enhance the daily lives and overall well-being of nearly a thousand individuals.

The National Institute for Health and Care Excellence has endorsed Produodopa drug for NHS use following its success in clinical trials.

Testimonials from participants, such as 70-year-old John Whipps, underscore the transformative impact of this treatment.

Whipps shared how the therapy has made his life more manageable, reducing his reliance on a complex regimen of pills and alleviating nocturnal symptoms.

Phil, another trial participant from Cornwall, echoed Whipps' sentiments. He recounted the challenges of managing his fluctuating symptoms with a regimen of 25 pills a day and the substantial improvement in his quality of life since using the pump, particularly during nighttime.

This new treatment promises not only to alleviate the burdens of medication management for those with advanced Parkinson's but also to offer an alternative for patients who currently depend on invasive methods of drug delivery.

According to the NHS, Parkinson's disease affects approximately 128,000 individuals across England.

Laura Cockram from the charity Parkinson's UK hailed Produodopa as a potentially "life-changing option" for patients, she however, advises individuals to consult healthcare professionals to determine if it is suitable for their specific condition.

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less